Terns Pharmaceuticals, Inc. (TERN) is a biopharmaceutical company that focuses on developing innovative small molecule therapies for liver diseases and other chronic conditions. As a leader in the field, Terns Pharmaceuticals utilizes a variety of technical analysis indicators to evaluate the performance of its stock. These indicators provide valuable insights into the market trends and help investors make informed decisions.

One of the key technical indicators used by Terns Pharmaceuticals is the Relative Strength Index (RSI). The RSI is a momentum oscillator that measures the speed and change of stock price movements. By analyzing the RSI, TERN can assess whether the stock is overbought or oversold, which can indicate potential price reversals.

Terns Pharmaceuticals (TERN) Technical Analysis

Learn about the technical indicators for Terns Pharmaceuticals, Inc. (TERN) stock, including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Check the analysis rating for TERN and make informed investment decisions. Gain insights into TERN's performance without any exploration or evaluation.

Terns Pharmaceuticals, Inc. (TERN) Technical Analysis: Indicators and Ratings

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	52.51	Neutral	50.7%
auto_graphMACD	17.16	Neutral	795.4%
auto_graphCCI	-49.77	Neutral	90.0%
auto_graphADX	27.29	Neutral	-
auto_graphATR	27.01	Buy	-
auto_graphWILLR	-67.32	Neutral	64.2%
auto_graphROC	-15.14	Sell	620.3%
auto_graphSTOCHRSI	0.00	Buy	24.7%

Buy	2	-75.00%
Hold	5	-37.50%
Sell	1	-87.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Terns Pharmaceuticals (TERN) Technical Analysis

Keep an eye on Terns Pharmaceuticals

Frequently Asked Questions

What are the technical signals for Terns Pharmaceuticals (TERN) stock based on the last 30 days?

Take Your Investments to a Whole New Level